This study aims to find out if a new drug, called tilpisertib fosmecarbil, helps treat ulcerative colitis (UC). UC is a condition where the colon, also known as the large intestine, becomes inflamed. People with moderate to severe UC will receive either the drug or a placebo—a pill with no medicine—to see which works better. The main goal is to see if there's a response at Week 12.

To join, you must be 18 to 75 years old and have had UC for at least 90 days. You need to have tried other UC treatments that didn't work well for you. The study lasts 12 weeks and requires multiple visits for check-ups and tests. Some people might not qualify if they have other health issues, like Crohn's Disease, or if they are taking certain medications.

• Study takes 12 weeks with several visits.
• You might get a placebo instead of the new drug.
• Eligibility depends on your previous treatment and current health status.